15.07.2010 • News

Novartis in $175 Million Gender Bias Settlement

Novartis has agreed to pay $175 million to settle a class-action lawsuit accusing the Swiss drugmaker of discriminating against 5,600 current and former female employees.

The settlement was announced less than two months after a Manhattan jury ordered Novartis to pay $250 million in punitive damages, after a six-week trial. That jury concluded the company's U.S. unit, Novartis Pharmaceuticals, engaged in a pattern of discrimination between 2002 and 2007.

Lawyers for the plaintiffs said it was the largest U.S. gender discrimination case ever to go to trial. In a joint statement with the plaintiffs' lawyers, Novartis said it will pay $152.5 million to eligible class members and pay an additional $22.5 million to improve companywide complaint processes, oversight and performance assessment.

The settlement requires court approval. U.S. District Judge Colleen McMahon scheduled a Nov. 19 hearing to consider whether to approve it.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.